全文获取类型
收费全文 | 11252篇 |
免费 | 802篇 |
国内免费 | 60篇 |
专业分类
耳鼻咽喉 | 80篇 |
儿科学 | 263篇 |
妇产科学 | 367篇 |
基础医学 | 1837篇 |
口腔科学 | 233篇 |
临床医学 | 1032篇 |
内科学 | 2318篇 |
皮肤病学 | 149篇 |
神经病学 | 1087篇 |
特种医学 | 433篇 |
外国民族医学 | 1篇 |
外科学 | 1796篇 |
综合类 | 117篇 |
一般理论 | 15篇 |
预防医学 | 781篇 |
眼科学 | 271篇 |
药学 | 672篇 |
中国医学 | 4篇 |
肿瘤学 | 658篇 |
出版年
2022年 | 99篇 |
2021年 | 193篇 |
2020年 | 101篇 |
2019年 | 179篇 |
2018年 | 245篇 |
2017年 | 152篇 |
2016年 | 176篇 |
2015年 | 232篇 |
2014年 | 336篇 |
2013年 | 433篇 |
2012年 | 567篇 |
2011年 | 619篇 |
2010年 | 348篇 |
2009年 | 294篇 |
2008年 | 578篇 |
2007年 | 605篇 |
2006年 | 589篇 |
2005年 | 530篇 |
2004年 | 601篇 |
2003年 | 526篇 |
2002年 | 492篇 |
2001年 | 220篇 |
2000年 | 244篇 |
1999年 | 234篇 |
1998年 | 118篇 |
1997年 | 80篇 |
1996年 | 89篇 |
1995年 | 91篇 |
1994年 | 77篇 |
1992年 | 123篇 |
1991年 | 104篇 |
1990年 | 122篇 |
1989年 | 121篇 |
1988年 | 123篇 |
1987年 | 101篇 |
1986年 | 116篇 |
1985年 | 110篇 |
1984年 | 101篇 |
1983年 | 80篇 |
1982年 | 76篇 |
1981年 | 71篇 |
1980年 | 58篇 |
1979年 | 74篇 |
1978年 | 60篇 |
1977年 | 76篇 |
1975年 | 61篇 |
1974年 | 62篇 |
1973年 | 67篇 |
1970年 | 57篇 |
1968年 | 58篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Hans D de Boer Jan van Egmond Jacques J Driessen Leo HD Booij 《Neuropsychiatric Disease and Treatment》2007,3(5):539-544
Steroidal neuromuscular blocking agents (NMBAs), such as rocuronium, are widely used in clinical anesthesia and emergency medicine to facilitate endotracheal intubation and artificial ventilation and to allow surgical access to body cavities. Reversal of neuromuscular blockade is important for the acceleration of patient recovery and prevention of postoperative residual neuromuscular blockade and reduces the incidence of severe morbidity and mortality associated with anesthesia management. Sugammadex is the first selective relaxant binding agent (SRBA) and has been designed to reverse the steroidal neuromuscular blocking drug rocuronium. Encapsulation of the rocuronium molecule by sugammadex results in a rapid decrease in free rocuronium in the plasma and subsequently at the nicotinic receptor at the motor endplate. After encapsulation, rocuronium is not available to bind to the nicotinic receptor in the neuromuscular junction. This promotes the liberation of acetylcholine receptors, and muscle activity reappears. This new concept of reversal of neuromuscular block induced by rocuronium (or vecuronium) led to impressive results in animal and phase 1 and 2 studies. Sugammadex is currently in phase 3 clinical studies and may be commercially available by 2008. 相似文献
12.
13.
Practical management of patients with non-small-cell lung cancer treated with gefitinib. 总被引:7,自引:0,他引:7
Neelam T Shah Mark G Kris William Pao Leslie B Tyson Barbara M Pizzo Murk-Hein Heinemann Leah Ben-Porat Dana L Sachs Robert T Heelan Vincent A Miller 《Journal of clinical oncology》2005,23(1):165-174
PURPOSE: The use of gefitinib, the first drug approved to inhibit the epidermal growth factor receptor tyrosine kinase, is indicated in patients with non-small-cell lung cancer with tumors progressive after chemotherapy. The unique mechanism of action of this agent leads to distinctive patterns of response and toxicity in persons with lung cancer. Many of the principles of management relevant to gefitinib are distinct from those with conventional cytotoxic drugs. To meet this need, we present practical guidelines on the use of gefitinib in patients with non-small-cell lung cancer. METHODS: This article reviews gefitinib's indications, dosing, response phenomena, and patterns of relapse in individuals with radiographic response. RESULTS: We present our recommendations for the management of rash and diarrhea caused by this agent. CONCLUSION: This information can guide practitioners and help them inform their patients about what to expect when they receive gefitinib. 相似文献
14.
15.
16.
De Leo V; Morgante G; Lanzetta D; D'Antona D; Bertieri RS 《Human reproduction (Oxford, England)》1997,12(2):357-360
We report the results of administration of danazol after suspension of
gonadotrophin-releasing hormone analogue (GnRHa) therapy for uterine
myomas. A total of 21 women with uterine myomas was treated with 100 mg
danazol for 6 months after GnRHa therapy. Uterine volume and endocrine
status were monitored monthly by ultrasound and assay of plasma
gonadotrophins, oestradiol and progesterone. The results show a rebound of
uterine volume about 30% less than in controls at the end of danazol
therapy. Menstrual cyclicity returned after 65 +/- 3 days in 16 subjects
and five patients remained amenorrhoeic. Hormone assays confirmed renewed
ovarian function in the women whose menstrual periods returned. Bone
mineral content was substantially reduced during GnRHa treatment but
improved significantly during danazol therapy even in the women who
remained amenorrhoeic. These results show the utility of danazol in
prolonging the therapeutic effects of GnRHa. The mechanism by which danazol
inhibits rebound of uterine volume may be due to its antiprogesterone
effects on uterine myomas.
相似文献
17.
18.
19.
20.